Unum Therapeutics, Inc.
|Number of Estimates|
Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.
Market Cap: 9.8 Million
Primary Exchange: NASDAQ
Shares Outstanding: 30.6 Million
Float: 13.6 Million
Sector: Health Technology
Longest drawdown: 947 trading days
From: 2018-07-31 To: 2020-04-03
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|